Atypical Carcinoid Tumor of the Lung: A Surveillance, Epidemiology, and End Results Database Analysis  by Steuer, Conor E. et al.
479Journal of Thoracic Oncology ®  •  Volume 10, Number 3, March 2015
Background: Atypical carcinoid (AC) of the lung is a rare form of 
thoracic malignancy. The limited knowledge of its biology and out-
come stems largely from small, single institution experiences. We 
analyzed the Surveillance, Epidemiology, and End Results database 
(SEER) to better understand the clinical characteristics of this disease.
Methods: Demographic, treatment, and outcome data on all 
patients with pulmonary AC were obtained from the SEER database 
with 18 reporting sites from 1973 to 2010 using SEER*Stat 8.1.2. 
Statistical analysis was performed using SAS 9.3 (SAS Institute, 
Inc., Cary, NC).
Results: There were 947,463 patients diagnosed with lung and bron-
chus tumors in the SEER database, of which 441 had AC (0.05%). 
Median age of AC patients was 65 years; 69% were women and 87% 
of white ethnicity. Metastatic disease was present in 20% of patients 
at diagnosis. In terms of treatment, 78% of patients underwent resec-
tion and 12.5% received radiation. The overall 1-year and 3-year sur-
vival rates were 86% and 67%, respectively. The 3-year survival rates 
for distant (M1), regional (lymph node involvement), and localized 
(lung only) disease were 26% (13 of 50), 69% (50 of 72), and 85% 
(99 of 116), respectively. On univariate analysis, patients treated with 
surgery had reduced risk of death (hazard ratio, HR 0.19; p < 0.001), 
whereas radiation treatment was associated with increased risk of 
death (HR 2.45; p < 0.001).
Conclusions: AC accounted for less than 1% of all lung cancers 
diagnosed and was more frequent in women. The best outcomes were 
observed with surgical resection for localized disease.
Key Words: Atypical carcinoid, Non–small-cell lung cancer, 
Outcomes, SEER, Neuroendocrine, Lung cancer.
(J Thorac Oncol. 2015;10: 479–485)
Atypical carcinoid (AC) tumor of the lung is a rare sub-type of lung cancer. It is estimated that carcinoid tumors 
overall encompass 1% to 5% of all lung neoplasms, and AC 
represents 10% of this subpopulation.1 These tumors belong 
to a spectrum of pulmonary neuroendocrine tumors (NET) 
which include, in order of most differentiated to least dif-
ferentiated, typical carcinoid (TC), AC, large cell neuroen-
docrine carcinoma (LCNEC), and small cell carcinoma.2 AC 
tumors were first defined in 1972,3 but the classification was 
not standardized until 1998. A comprehensive examination of 
the histopathologic and clinical characteristics of 200 cases 
of pulmonary NET led to a clinically relevant definition of 
AC by Travis et al. with the requirement for a neuroendocrine 
morphology and either coagulative necrosis or mitotic counts 
of 2 to 10 per 2 mm2 of viable tumor.4 This definition was sub-
sequently incorporated into the World Health Organization 
(WHO) and the International Association for the Study of 
Lung Cancer classifications of lung neoplasms. The overall 
low prevalence of the disease has curtailed our understanding 
of the clinical risk factors and prognosis of AC.
Available information suggests that patients with AC 
tumors often present with early stage disease, and surgical 
resection is the preferred treatment modality. However, the 
body of literature on AC largely comes from surgical series 
and therefore remains skewed toward earlier stage disease 
with overall better outcomes. The effectiveness of radiation 
and/or chemotherapy for AC is unknown, either alone or in 
adjunct with surgery.5
Given its rarity and the resulting paucity of data on prog-
nosis and optimal management, we sought to better understand 
pulmonary AC by using the Surveillance, Epidemiology, and 
End Results (SEER) Program of the National Cancer Institute 
to investigate clinical characteristics and outcomes of patients 
with this specific tumor type.
METHODS
Data Source
This analysis was performed using the SEER public-use 
database, including the 18 SEER registries and SEER*Stat 
8.1.2 data sets from 1973 to 2010. However, pulmonary AC 
cases were only available in SEER beginning in 2001 second-
ary to the standardization in the histological coding of AC at 
that time.4 The SEER program is sponsored by the National 
Cancer Institute and collects information regarding cancer 
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incidence and survival from 18 population-based cancer reg-
istries that cover approximately 28% of the U.S. population.6
Patient Population
All patients with a diagnosis of lung and bronchus can-
cer classified according to the ICD-0–3/WHO 2008 criteria 
between years 1973 and 2010 were identified in the SEER 
database for this study. We identified the cases with this diag-
nosis and extracted the relevant data using the case listing ses-
sion of SEER*Stat 8.1.2 software. From this group, patients 
with an ICD-0–3 histology diagnosis of AC tumor were iden-
tified and employed for the primary analysis. To provide a 
broad, clinically relevant characterization of pulmonary AC, 
none of these patients were excluded from the study.
Statistical Analysis
Baseline patient characteristics were compared by sum-
mary stage (localized, regional, and distant) using Kruskal–
Wallis test for continuous variables, i.e., age at diagnosis, and 
chi-square test of Fisher’s exact test for categorical variables, 
as applicable. Age at diagnosis, gender, race, grade, stage, 
summary stage, Contract Health Service Delivery Areas 
(CHSDA) regions, primary site, surgery of primary site, and 
radiation variables were included in the survival analysis mod-
els. Survival functions were estimated by the Kaplan–Meier 
method and the log-rank test was used to assess the differences 
in overall survival (OS) stratified by each covariate.7 Univariate 
and multivariable survival analyses were conducted using the 
Cox proportional hazards model.8 Multivariable analysis was 
conducted by entering race, gender, primary site, radiation, and 
CHSDA region into the Cox proportional hazards model. The 
best predictive model of OS was identified using a backward 
variable selection method with an alpha level of removal of 0.1. 
The model was stratified by summary stage since it was shown 
to be a time-dependent covariate and by age at diagnosis.
All analyses were done using SAS 9.3 (SAS Institute, 
Inc., Cary, NC) with a statistical significant level of 0.05.
RESULTS
First, we examined the clinical characteristics of patients 
presenting with pulmonary AC. A total of 947,463 cases of 
lung and bronchus tumors were identified and 441 of them 
were AC. Demographic data for all the AC patients are shown 
in Table 1. The median age for all the AC patients was 65 
years (range, 21–90); 87% patients were white and 8.5% were 
African American (AA). Women represented a majority of the 
patients (68.7%). All the analyses were conducted using the 
SEER historic stage A system classification, as the American 
Joint Committee on Cancer (AJCC) 6th edition was missing 
a significant amount of data. SEER historic stage A catego-
rizes disease as local (tumor in lung only), regional (pulmo-
nary lymph node involvement), or distant (M1). In all, 48.7% 
patients were categorized with localized disease and 20% with 
distant disease. Regarding treatment, 77.5% of patients were 
managed by surgery, and 12.5% received radiation treatment. 
Of the patients who were treated with surgery, 21.5% had a 
sub-lobar resection, whereas 78.5% had a lobectomy, bilobec-
tomy, or pneumonectomy.
Next, we compared the demographic and clinical char-
acteristics across tumor stages. The distribution by stage of 
AC was not significantly different for race, sex, or region 
(Table 2). However, patients who presented with distant 
disease were significantly older (p = 0.006), more likely to 
receive radiation (p < 0.001), and less likely to undergo surgi-
cal resection (p < 0.001).
The overall 1-year and 3-year survival rate was 86% 
(n = 374) and 67% (n = 254), respectively. As with other 
lung cancer histologies, patients who presented with more 
advanced stages of disease had inferior outcomes: The 1-year 
and 3-year survival rate for patients with local disease was 
92% and 85%, respectively, compared with just 61% and 
TABLE 1.  Patient Demographics and Clinical Characteristics
Variable Level AC, n (%)
Age at diagnosis Median (range) 65 (21–90)
Race Black 37 (8.47)
Other 19 (4.35)
White 381 (87.19)
Sex Male 138 (31.29)
Female 303 (68.71)
CHSDA region East 200 (45.35)
Northern plains 46 (10.43)
Pacific coast 167 (37.87)
Southwest 28 (6.35)
Primary site Main bronchus 10 (2.27)
Upper lobe, lung 151 (34.24)
Middle lobe, lung 61 (13.83)
Lower lobe, lung 177 (40.14)
Overlapping lesion of lung 10 (2.27)
Lung, NOS 32 (7.26)












Radiation Yes 54 (12.5)
No 378 (87.5)
Surgery of primary site Yes 341 (77.5)
No 99 (22.5)
 Surgery type Segmental resection 13 (3.88)
Wedge resection 59 (17.61)
Lobectomy or bilobectomy 247 (73.73)
Pneumonectomy 16 (4.78)
AC, atypical carcinoid; AJCC, American Joint Committee on Cancer; NOS, not 
otherwise specified.
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26% in patients with distant disease (Table 3). Kaplan–Meier 
curves for survival in the overall population and stratified by 
SEER historic stage A classification are shown in Figures 1 
and 2. Survival for these figures was calculated from date 
of diagnosis until date of death or date of last follow-up. 
However, for the 1-year and 3-year survival rates, only 
patients with complete survival data were included.
Univariate and multivariate analyses were performed to 
examine the effect of each clinical variable on overall survival. 
On univariate analysis, older age (hazard ratio, HR 1.03; 95% 
confidence interval [CI]: 1.02–1.05; p < 0.001) was associated 
with worse outcome. Patients with metastatic (HR 6.72; 95% 
CI: 4.45–10.15; p < 0.001) and regional (HR 1.94; 95% CI: 
1.26–2.96; p = 0.002) disease fared worse as compared with 
patients with localized disease. Interestingly, AA patients had a 
significantly higher risk of death (HR 1.931; 95% CI: 1.13–3.33; 
p = 0.017). In addition, patients who underwent surgery had a 
higher likelihood of survival in univariate analysis (HR 0.19; 
95% CI: 0.14–0.26; p < 0.001) (Table 4). In the multivariate 
analysis that included age and summary stage as covariates, 
patients who received radiation exhibited worse survival out-
comes (multivariate HR 1.42; 95% CI: 0.90–2.24; p = 0.13), 
which was significant in the univariate analysis (HR 2.44; 95% 
CI: 1.65–3.63; p < 0.001) (Table 5). Interestingly, when sub-
lobar resections were compared with lobectomy or greater sur-
geries, there was no significant difference in survival in either 
univariate (p = 0.446) or multivariate analysis (p = 0.740). 
There was also a nonsignificant trend toward worse survival in 
AA relative to whites (HR 1.58; 95% CI: 0.88–2.83; p = 0.126).
DISCUSSION
Pulmonary AC tumors are rare, and relatively little is 
known about them compared with other types of lung cancer. 
By using the SEER database, we sought to define the demo-
graphic characteristics of patients who develop AC. We found 
that women represented the majority of our cohort. Interestingly, 
this does not follow the pattern observed with lung cancer over-
all, where of an estimated 224,210 of new cases in 2014, only 
48% (108,210) are estimated to be women.9 The female major-
ity seen in our study was not demonstrated in two previous 
large surgical series, where women constituted 46% and 50% 
of the population.10, 11 This difference may reflect the fact that 
the SEER database is more representative and capture patients 
at all stages of disease. Nonetheless, the majority of AC patients 
in this study present with early stage, resectable disease, consis-
tent with prior reports.12, 13 Our reported rate of distant metas-
tasis for AC (20%) was consistent with that found by Gridelli 
TABLE 2.  Patient Characteristics by Stage
Covariate Level All Patients (n = 441)
Summary Stage
p ValueaLocalized (n = 203) Regional (n = 131) Distant (n = 83)
Age at diagnosis Median (range) 65 (21–90) 65 (24–90) 61 (21–87) 67 (40–86) 0.006
Race Black 37 (8.47) 17 (8.5) 9 (6.87) 10 (12.05) 0.385
Other 19 (4.35) 11 (5.5) 6 (4.58) 1 (1.2)
White 381 (87.19) 172 (86) 116 (88.55) 72 (86.75)
Sex Female 303 (68.71) 138 (67.98) 86 (65.65) 59 (71.08) 0.708
Male 138 (31.29) 65 (32.02) 45 (34.35) 24 (28.92)
CHSDA region East 200 (45.35) 90 (44.33) 55 (41.98) 41 (49.4) 0.423
Northern Plains 46 (10.43) 24 (11.82) 10 (7.63) 10 (12.05)
Pacific Coast 167 (37.87) 79 (38.92) 55 (41.98) 25 (30.12)
Southwest 28 (6.35) 10 (4.93) 11 (8.4) 7 (8.43)
Primary site Lower lobe 177 (40.14) 89 (43.84) 53 (40.46) 27 (32.53) <0.001
Lung, NOS 32 (7.26) 5 (2.46) 9 (6.87) 14 (16.87)
Main bronchus 10 (2.27) 3 (1.48) 3 (2.29) 3 (3.61)
Middle lobe 61 (13.83) 34 (16.75) 15 (11.45) 8 (9.64)
Overlapping lesion 10 (2.27) 2 (0.99) 7 (5.34) 1 (1.2)
Upper lobe 151 (34.24) 70 (34.48) 44 (33.59) 30 (36.14)
Radiation No 378 (87.5) 193 (96.02) 102 (80.31) 61 (75.31) <0.001
Yes 54 (12.5) 8 (3.98) 25 (19.69) 20 (24.69)
Surgery of primary 
site
No 99 (22.5) 17 (8.37) 13 (9.92) 53 (63.86) <0.001
Yes 341 (77.5) 186 (91.63) 118 (90.08) 30 (36.14)
Data are presented as number of patients (%), mean (±SD), or median (range). The bolded values represent values that reached statistical significance.
aThe p value is calculated by Kruskal–Wallis test for age at diagnosis and chi-square test or Fisher’s exact test for categorical covariates.
TABLE 3.  1- and 3-Year Survival Rates
Summary Stage 1 Year (n) 3 Years (n)
Overall population 86% (322/374) 67% (170/254)
Localized 92% (156/169) 85% (99/116)
Regional 94% (103/110) 69% (50/72)
Distant 61% (45/74) 26% (13/50)
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et al. (20%), which reported that the rate of metastatic disease 
was 3% for TC and 40% for LCNEC.14 This intermediate rate 
for AC metastasis supports the notion that AC constitutes a dis-
tinct prognostic subgroup within the NET spectrum.
Surgical resection is the mainstay of treatment for AC, 
with lobectomy being the most commonly performed proce-
dure.15 In our study, 78% of our patients underwent surgery, 
with the majority of those cases having localized or regional 
disease. Remarkably, previous studies recorded a recurrence 
of AC in 20% to 25% of patients treated with surgery15–17 
with a 5-year survival ranging from 65% to 90%.18–20 It was 
interesting to note that there was no survival difference in our 
study between patients who underwent a sub-lobar resection 
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controlling for stage and age. This finding is consistent with 
prior SEER studies that had a larger focus on TC tumors.21, 
22 However, Canizares et al. reported an increased rate of 
locoregional recurrence for patients with AC who underwent 
sub-lobar resection, but this did not translate to a significant 
difference in overall survival.10 Taken together with our results, 
these findings imply that sub-lobar resections may be accept-
able if lobectomy cannot be performed. Conversely, not much 
is currently known regarding the treatment and outcomes for 
patients with more advanced stages of AC, as most published 
data came from surgical series. Forde et al. reported on 49 
patients with locally advanced or metastatic carcinoid tumors 
(32 AC, 17 TC) and found a median survival of 4 years for AC 
versus the 10.2-year median survival described in TC tumors.23
Several studies have attempted to identify prognostic vari-
ables in carcinoid tumors. AC histology has been consistently 
shown to confer worse outcomes compared with TC.15, 24 Within 
the AC histology, specific prognostic variables are less known. 
However, lymph node involvement of AC has been repeatedly 
shown to be a negative prognostic factor. In one study, lymph 
node involvement (HR 0.46; p = 0.008), as well as age and 
tobacco use, was associated with decreased survival probabil-
ity in AC.11 Consistent with prior reports, both older age and 
higher tumor stage showed a significant negative association 
with survival in our large data set. Curiously, AA showed a 
significantly increased mortality risk compared with whites, a 
trend that persisted even after controlling for the potential con-
founding effect of age and tumor stage. To our knowledge, this 
is the first report that African Americans fare worse with AC 
and a similar observation to the 17% increase in mortality rate 
reported in African Americans diagnosed with non–small-cell 
lung cancer. Socioeconomic status, biological differences, and 
TABLE 4.  Univariate Analysis of Overall Survival
Variables Level n HR (95% CI) HR p Value
Age at diagnosis 441 1.03 (1.02–1.05) <0.001
Age at diagnosis Age >65 213 1.56 (1.13–2.16) 0.006
Age ≤65 228 1 –
Race Black 37 1.94 (1.13–3.33) 0.017
White 381 1 –
Sex Male 138 1.22 (0.87–1.71) 0.241
Female 303 1 –
CHSDA region East 200 0.62 (0.34–1.14) 0.124
Northern plains 46 0.82 (0.41–1.67) 0.590
Pacific coast 167 0.58 (0.32–1.07) 0.083
Southwest 28 1 –
Primary site Main bronchus 10 3.67 (1.37–9.84) 0.010
Upper lobe, lung 151 1.95 (1.04–3.65) 0.038
Lower lobe, lung 177 1.85 (0.99–3.47) 0.054
Overlapping lesion of lung 10 1.98 (0.70–5.66) 0.200
Lung, NOS 32 5.42 (2.65–11.10) <0.001
Middle lobe, lung 61 1 –
AJCC Stage 6 IA 123 0.11 (0.06–0.20) <0.001
IB 42 0.16 (0.07–0.36) <0.001
IIA 14 0.15 (0.05–0.50) 0.002
IIB 15 0.22 (0.07–0.73) 0.013
IIIA 37 0.27 (0.14–0.53) <0.001
IIIB 26 0.38 (0.18–0.80) 0.010
IV 56 1 –
Summary stage Distant 83 6.72 (4.45–10.15) <0.001
Regional 131 1.94 (1.26–2.96) 0.002
Localized 203 1 –
Radiation Yes 54 2.44 (1.65–3.63) <0.001
No 378 1 –
Surgery of primary site Yes 341 0.19 (0.137–0.264) <0.001
No 99 1
Surgery type Sublobar resection 72 1.23 (0.72–2.11) 0.446
Lobectomy or greater 263 1 –
The bolded values represent values that reached statistical significance.
AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio.
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varying drug efficacy have all been proposed to contribute to 
this disparity,25 but we were unable to assess the role of these 
factors in this retrospective database analysis.
We also found that patients who underwent surgery had 
improved outcomes, whereas those who received radiation 
had worse overall survival. However, in clinical practice the 
use of radiation for patients with AC is usually reserved for 
unresectable patients or those with serious comorbid condi-
tions that are associated with a higher mortality unrelated to 
the primary diagnosis. Therefore, our findings probably reflect 
the fact that patients with poor prognosis receive radiation, 
rather than ineffectiveness of radiation therapy in this disease, 
although we are unable to completely exclude the possibility 
that radiation-induced toxicity contributed to the adverse out-
come in this category of patients.
Although using the SEER database has allowed for 
an exploratory analysis of a rare form of lung cancer, it is 
important to understand some of its limitations. First, as 
with any national database, details of important clinical 
variables that affect outcome and ability to undergo cura-
tive surgical resection such as smoking and performance 
status are not available. The database is also reliant on the 
individual reporting institutions to accurately identify the 
AC diagnosis. Therefore, although the pathological defini-
tion of AC was standardized in 1998, the possibility of mis-
classification within SEER exists. In addition, the efficacy 
of chemotherapy in AC in the adjuvant or palliative setting 
has not been established. Unfortunately, chemotherapy 
data are unavailable from the database, thus limiting this 
study’s ability to describe treatment patterns in AC; simi-
larly, responses to treatment and recurrence rates could not 
be ascertained from SEER.
In conclusion, this analysis of a representative database 
of U.S. population showed that pulmonary AC is an uncom-
mon lung neoplasm. A significant proportion of these patients 
presented with metastatic disease (20%) and it occurred more 
frequently in women. Older age, advanced stage, and African 
American race were identified as negative prognostic factors. 
As the largest series to date on the clinical characteristics and 
outcome of AC, we believe that the important findings from 
our study will inform future management and prospective 
studies in this patient population.
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